Advanced therapies
- April 07
Advanced therapies include gene therapy, somatic cell therapy, and tissue engineering. The European Commission proposed regulation of these innovative therapies. Regulation is beneficial for rare disease patients.
Eurordis responded to a public consultation on the Regulation, expressing support for most of the proposed provisions. Eurordis’ reservations included concerns about the proposed Risk Management System, and a fear that the system may generate too many additional regulatory constraints. The regulation was adopted by the European Parliament on 25 April 2007.
Read press release following adoption of the Regulation - April 2007 >
Read European Patients’ Statement of April 2007 >
Read Call to MEPs to support the compromise package (April 2007) >
For more information:
Eurordis' newsletter article "Two EURORDIS representatives appointed to the Committee for Advanced Therapies" (April 2009)
Eurordis’ newsletter article - March 2006
